ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,972.30
0.05%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Genuit Group Plc (GEN)

  7. Genuit Group Plc (GEN) Noticias

GEN

Genuit (GEN)

Genuit Group Plc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:GEN
FechaHoraFuenteTítuloSímboloCompañía
14/05/202402:00PR Newswire (US)Deepfakes, AI-Manipulated Audio, and Hijacked Social Media Surge in 2024LSE:GENGenuit Group Plc
02/05/202410:57RNS Regulatory NewsGenuit Group PLC Block listing Interim ReviewLSE:GENGenuit Group Plc
24/04/202404:39RNS Regulatory NewsGenuit Group PLC Notice of AGMLSE:GENGenuit Group Plc
10/04/202410:24RNS Regulatory NewsGenuit Group PLC Director/PDMR ShareholdingLSE:GENGenuit Group Plc
09/04/202410:28RNS Regulatory NewsGenuit Group PLC Director DeclarationLSE:GENGenuit Group Plc
12/03/202405:40Alliance NewsAlliance NewsGenuit revenue drops on lower divisional sales but profit surgesLSE:GENGenuit Group Plc
12/03/202402:09Alliance NewsAlliance News*Genuit says 2024 trading has started in line w/ expectations, despite market uncertaintyLSE:GENGenuit Group Plc
12/03/202402:09Alliance NewsAlliance News*Genuit declares total dividend per share of 12.4p vs 12.3p YoYLSE:GENGenuit Group Plc
12/03/202402:07Alliance NewsAlliance News*Genuit 2023 pretax profit GBP48.4m vs GBP45.4m YoYLSE:GENGenuit Group Plc
12/03/202402:00RNS Regulatory NewsGenuit Group PLC Final ResultsLSE:GENGenuit Group Plc
19/02/202403:00RNS Regulatory NewsGenuit Group PLC Notice of Results and Investor PresentationLSE:GENGenuit Group Plc
23/01/202409:49UK RegulatoryGenuit Group PLC Holding(s) in CompanyLSE:GENGenuit Group Plc
23/01/202405:24UK RegulatoryGenmab A/S Genmab Announces Net Sales Of Darzalex(R) (daratumumab) For 2023LSE:GENGenuit Group Plc
22/01/202417:40UK RegulatoryGenmab A/S Genmab Announces Decision In Arbitration Appeal Under License Agreement With JanssenLSE:GENGenuit Group Plc
09/01/202405:45UK RegulatoryGenmab A/S Tivdak(R) (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted For Priority Review By U.S. Food And Drug Administration For Patients With Recurrent Or Metastatic Cervical CancerLSE:GENGenuit Group Plc
02/01/202423:55UK RegulatoryGenmab A/S Transactions With Shares And Linked Securities In Genmab A/S Made By Managerial Employees And Their Closely Associated PersonsLSE:GENGenuit Group Plc
02/01/202408:52UK RegulatoryGenmab A/S Genmab To Present At The 42nd Annual J.P. Morgan Healthcare ConferenceLSE:GENGenuit Group Plc
12/12/202306:00UK RegulatoryGenmab A/S Genmab To Hold 2023 R&D Update And Ash Data Review MeetingLSE:GENGenuit Group Plc
09/12/202311:00UK RegulatoryGenmab A/S New Pivotal Data For Bispecific Antibody Epcoritamab (DuoBody(R) Cd3xcd20) Demonstrates High Overall And Complete Responses In Patients With Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)LSE:GENGenuit Group Plc
05/12/202316:26UK RegulatoryGenmab A/S Capital Increase In Genmab As A Result Of Employee Warrant ExerciseLSE:GENGenuit Group Plc
27/11/202306:00UK RegulatoryGenmab A/S Genmab Announces Positive Regulatory Updates For Epcoritamab (EPKINLY(R)/Tepkinly(R)) For The Treatment Of Relapsed/Refractory Follicular LymphomaLSE:GENGenuit Group Plc
22/11/202301:00UK RegulatoryGenuit Group PLC Strategy Progress Update NotificationLSE:GENGenuit Group Plc
21/11/202315:42UK RegulatoryGenmab A/S Grant Of Restricted Stock Units To Board Members And Employees And Grant Of Warrants To Employees In GenmabLSE:GENGenuit Group Plc
15/11/202303:03Alliance NewsAlliance NewsGenuit shares rise as annual profit predicted to exceed expectationsLSE:GENGenuit Group Plc
15/11/202301:00UK RegulatoryGenuit Group PLC Trading UpdateLSE:GENGenuit Group Plc
09/11/202308:14UK RegulatoryGenmab A/S Major Shareholder AnnouncementLSE:GENGenuit Group Plc
09/11/202304:00UK RegulatoryGenmab A/S Genmab To Present At Jefferies London Healthcare ConferenceLSE:GENGenuit Group Plc
07/11/202310:01UK RegulatoryGenmab A/S Genmab Announces Financial Results For The First Nine Months Of 2023LSE:GENGenuit Group Plc
02/11/202308:05UK RegulatoryGenmab A/S Genmab Announces Multiple Abstracts To Be Presented At The 65th Annual Meeting And Exposition Of The American Society Of Hematology (ASH)LSE:GENGenuit Group Plc
01/11/202305:58Alliance NewsAlliance NewsIN BRIEF: Genuit confirms interim CFO Tim Pullen as permanent CFOLSE:GENGenuit Group Plc
 Showing the most relevant articles for your search:LSE:GEN

Su Consulta Reciente

NASDAQ
FTLK
BOV
PAGS34Q
PagSeguro Digital
GDAX
ICPEUR
Internet Computer
GATE
DEVTUSDT
Decentralized Eternal Virtual Tr
AMEX
IQSU
IQ Candriam US Large Cap...
COIN
DRIPPPUST
DRIP Token
LSE
10I8
BMF
OC1F29
OC1F29 - Janeiro 2029
COIN
NYANEUR
HUOB
WAXLUSDT
Axelar
CRTO
CRVBTC
Curve DAO Token
LSE
LC35
Anz Bank 23
BIT
UV4KSW
UniCredit Bank
UNSW
ALCHETH
Alchemy
TSX
SOLG
SolGold
BIT
UC5274
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados